Analysts expect over 2020 decreasing revenue Morphosys

Tomorrow the German Morphosys will report its past quarter results. Over the current book year the total revenue will be 71,66 million euros (consensus estimates). This is slightly lower than 2018's revenue of 76,44 million euros.

Historical revenues and results Morphosys plus estimates 2020

equity research

The analysts expect for 2020 a net loss of 98 million euros. The majority of the analysts expects for this year a loss per share of 3,1 euros. The price-earnings-ratio equals -24,94.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0,59 percent.

Most recent target prices around 130 euros

The latest 3 recommendations for the biotech company were provided by Berenberg, Barclays and Independent Research.

Morphosys 's market value equals around 2,25 billion . The Morphosys stock was the past 12 months quite volatile. Since last March the stock is 8 percent lower. This year the stock price moved between 70 and 146 euro. Since 2008 the stock price is almost 368 percent higher.

Historical stock prices Morphosys from 2007 till 2020

equity research morphosys

Click here for dividend . At 12.00 the stock trades 7,24 percent lower at 77,3 euros. Nieuwsdienst: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.